busulfan has been researched along with Liver Dysfunction in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Transfusion of platelet concentrates containing ABO-incompatible plasma increases the risk of hepatic veno-occlusive disease in young children treated with a busulfan-containing regimen." | 3.73 | Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. ( Aupérin, A; Benhamou, E; Hartmann, O; Lapierre, V; Mahé, C; Oubouzar, N; Stambouli, F; Tiberghien, P; Tramalloni, D, 2005) |
| " In the (T)BU/CY patients only, the association of the pharmacokinetic data with liver toxicity, relapse, and survival was evaluated." | 2.73 | Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. ( Batchelder, A; Cole, S; Deeg, HJ; Gooley, T; McCune, JS; McDonald, GB; Phillips, B; Schoch, HG, 2007) |
| "Hyperbilirubinemia was graded according to a report by Hogan et al (Blood." | 1.33 | Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases. ( Fujiwara, M; Hori, A; Kami, M; Kanda, Y; Komatsu, T; Koyama, R; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Murashige, N; Seki, K; Tanaka, Y; Taniguchi, S; Wake, A; Yuji, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Simon, N | 1 |
| Coiteux, V | 1 |
| Bruno, B | 1 |
| Taque, S | 1 |
| Charbonnier, A | 1 |
| Souchet, L | 1 |
| Vincent, L | 1 |
| Yakoub-Agha, I | 1 |
| Chalandon, Y | 1 |
| Duchartre, Y | 1 |
| Petit, N | 1 |
| Moya, C | 1 |
| Lalanne, M | 1 |
| Dubus, P | 1 |
| Verneuil, Hd | 1 |
| Moreau-Gaudry, F | 1 |
| Richard, E | 1 |
| OISHI, N | 1 |
| SWISHER, SN | 1 |
| TROUP, SB | 1 |
| Lapierre, V | 1 |
| Mahé, C | 1 |
| Aupérin, A | 2 |
| Stambouli, F | 1 |
| Oubouzar, N | 1 |
| Tramalloni, D | 1 |
| Benhamou, E | 2 |
| Tiberghien, P | 1 |
| Hartmann, O | 2 |
| Kusumi, E | 1 |
| Kami, M | 1 |
| Kanda, Y | 1 |
| Murashige, N | 1 |
| Seki, K | 1 |
| Fujiwara, M | 1 |
| Koyama, R | 1 |
| Komatsu, T | 1 |
| Hori, A | 1 |
| Tanaka, Y | 1 |
| Yuji, K | 1 |
| Matsumura, T | 1 |
| Masuoka, K | 1 |
| Wake, A | 1 |
| Miyakoshi, S | 1 |
| Taniguchi, S | 1 |
| McCune, JS | 1 |
| Batchelder, A | 1 |
| Deeg, HJ | 1 |
| Gooley, T | 2 |
| Cole, S | 1 |
| Phillips, B | 1 |
| Schoch, HG | 1 |
| McDonald, GB | 2 |
| Giardini, C | 2 |
| Galimberti, M | 2 |
| Lucarelli, G | 2 |
| Polchi, P | 2 |
| Baronciani, D | 2 |
| Angelucci, E | 2 |
| Erer, B | 1 |
| Gaziev, D | 1 |
| Maiello, A | 1 |
| Styler, MJ | 1 |
| Crilley, P | 1 |
| Biggs, J | 1 |
| Moul, J | 1 |
| Copelan, E | 1 |
| Topolsky, D | 1 |
| Avalos, B | 1 |
| Penza, S | 1 |
| Sabol, P | 1 |
| Downs, K | 1 |
| Szer, J | 1 |
| Brodsky, I | 1 |
| Marks, DI | 1 |
| Lassau, N | 1 |
| Leclère, J | 1 |
| Bourhis, JH | 1 |
| Valteau-Couanet, D | 1 |
| Bosq, J | 1 |
| Ibrahim, A | 1 |
| Girinski, T | 1 |
| Pico, JL | 1 |
| Roche, A | 1 |
| Lee, JL | 1 |
| Bensinger, W | 1 |
| Schiffman, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes[NCT04859218] | 30 participants (Anticipated) | Interventional | 2023-11-30 | Recruiting | |||
| Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients[NCT03963999] | Phase 4 | 0 participants (Actual) | Interventional | 2020-04-01 | Withdrawn (stopped due to We did not receive grant funding. We will reapply in June of 2020) | ||
| Usefulness of Liver Stiffness Measurement in Predicting Hepatic Veno-Occlusive Disease Development in Patients Who Undergo HSCT: a Multicentric Prospective Study[NCT03426358] | 1,101 participants (Actual) | Interventional | 2015-04-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for busulfan and Liver Dysfunction
| Article | Year |
|---|---|
[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-T
Topics: Adult; Age Factors; Busulfan; Child; Comorbidity; Cyclophosphamide; Etoposide; France; Hematopoietic | 2017 |
2 trials available for busulfan and Liver Dysfunction
| Article | Year |
|---|---|
Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.
Topics: Administration, Oral; Adolescent; Adult; Aged; Busulfan; Chemical and Drug Induced Liver Injury; Cyc | 2007 |
Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Cyclo | 1999 |
8 other studies available for busulfan and Liver Dysfunction
| Article | Year |
|---|---|
Neonatal bone marrow transplantation prevents liver disease in a murine model of erythropoietic protoporphyria.
Topics: Animals; Animals, Newborn; Bone Marrow Transplantation; Busulfan; Disease Models, Animal; Disease Pr | 2011 |
Busulfan therapy in myeloid metaplasia.
Topics: Busulfan; Disease; Liver Diseases; Myeloproliferative Disorders; Primary Myelofibrosis; Spleen; Sple | 1960 |
Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children.
Topics: ABO Blood-Group System; Adolescent; Antineoplastic Agents; Brain Neoplasms; Busulfan; Chemical and D | 2005 |
Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Chemical and Drug In | 2006 |
Bone marrow transplantation in class 2 thalassemia patients.
Topics: Adolescent; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyc | 1993 |
CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Anticonvulsants; beta-Thalassemia; Blood | 1996 |
Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bone Marrow Transplantation; Busulfan; Child; Child, | 1996 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |
Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.
Topics: Adult; Busulfan; Child; Diagnosis, Differential; Female; Graft vs Host Disease; Hematopoietic Stem C | 1997 |